Want to join the conversation?
Drugmaker $AGN reported a wider 2Q16 loss as results were impacted by loss of exclusivity on Namenda IR. Net loss widened to $571.3MM or $1.44 per share from $312.7MM or $0.80 per share last year. Revenue grew to $3.68Bil from $3.63Bil, on strong performance in key brands and new product launches. Non-GAAP EPS slid to $3.35 from $3.67.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?